 | |
| Clinical data | |
|---|---|
| Trade names | Plenaxis |
| AHFS/Drugs.com | Monograph |
| Routes of administration | Intramuscular injection |
| Drug class | GnRH analogue;GnRH antagonist;Antigonadotropin |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 96–99% |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C72H95ClN14O14 |
| Molar mass | 1416.09 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Abarelix, sold under the brand namePlenaxis, is an injectablegonadotropin-releasing hormone antagonist (GnRH antagonist) which is marketed inGermany and theNetherlands. It is primarily used inoncology to reduce the amount oftestosterone made in patients with advanced symptomaticprostate cancer for which no other treatment options are available.[2][3]
It was originally marketed by Praecis Pharmaceuticals asPlenaxis,[2] and is now marketed by Speciality European Pharma in Germany[4] after receiving a marketing authorization in 2005. The drug was introduced in theUnited States in 2003, but was discontinued in this country in May 2005 due to poor sales and a higher-than-expected incidence of severeallergic reactions.[5] It remains marketed inGermany and theNetherlands however.[6]
 | Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |
